This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that are released from the biofilm by our technology are more readily cleared by the remainder of the host's immune system.

Provided are humanized antibodies that bind to the 2C7 epitope of Neisseria gonorrhoeae. Also provided are compositions and methods for treating Neisseria gonorrhoeae infection in a subject in need thereof.

The present invention is directed to polyclonal antibodies, specific for the capsular polysaccharides of Neisseria meningitidis serogroup X (NmX), wherein said antibodies are suitable for in vitro detection of Neisseria meningitidis serogroup X in biological fluids without culture. The invention also concerns said polyclonal antibodies in different diagnostic tests and methods, in order to detect NmX. The invention discloses also a rapid diagnostic test for detecting NmX in a biological fluid, as well as a method for obtaining polyclonal antibodies useful for detecting NmX in biological fluids such as cerebrospinal fluid, serum and urine

Methods and compositions useful in treating neurodegenerative disorders are based on septapeptides and extended forms thereof (or portions thereof) that exhibit chemokine activity with respect to microglial cell precursors.

Multivalent meningococcal conjugate vaccines are administered according to a schedule in which a first dose is administered to a patient aged between 0 and 12 months, and a second dose is administered to the patient aged between 12 and 24 months.

Described are a therapeutic monoclonal antibody specific for the Type Six Secretion System (T6SS) needle protein of Acinetobacter baumannii (A. baumannii) and methods of use. Specifically, the antibody specifically binds to hemolysin co-regulated protein (Hep). Further disclosed are methods of using an anti-Hep antibody for detecting A. baumannii in a sample as well as a mutant A. baumannii strain comprising a deletion or mutation in its genome such that said deletion or mutation interrupts the proper translation of its hep protein.

This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that are released from the biofilm by our technology are more readily cleared by the remainder of the host's immune system.

In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

The present invention discloses a Acinetobacter baumannii immunogenic protein and its composition and application. This invention provides a protein, comprising 39 amino acids of the N-terminal -helix part of the Ata protein transport functional domain of Acinetobacter baumannii and an adjuvant protein; amino acid sequence of said 39 amino acids of the N-terminal -helix part of the Ata protein transport functional domain of Acinetobacter baumannii is shown as the 127.sup.th-165.sup.th amino acid residues of SEQ ID NO:2. In present invention the 39 amino acids of the N-terminal -helix part of surface protein Ata (Acinetobacter trimeric autotransporter) of Acinetobacter baumannii, was took to fuse with CTB, and express in BL21. The protein was purified by a nickel column, and used to intraperitoneally immunize mouses by 2.5 g/mouse. Its immunogenicity and immunoprotection was verified through the animal experiments, which proves it has a good effect of anti-infection of Acinetobacter baumannii.

In this application is described a mutant Acinobacter baumannii strain having a deletion or mutation in its genome. The deletion or mutation interrupts the proper translation of the Hcp protein.